

Global Markets for Bioengineered Protein Drugs

Market Research Report | 2023-03-16 | 185 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

This report aims to provide a comprehensive study of the global market for bioengineered protein drugs, both in terms of quantitative and qualitative data, to help readers develop business/growth strategies, assess the market landscape, analyze their position in the current marketplace and make informed business decisions regarding bioengineered protein drugs. Segmentation is based on the drug type, disease type, and region.

Industry growth drivers, restraints, trends, and opportunities in bioengineered protein drugs are also discussed in detail. The report also provides information on the bioengineered protein drug market competitive landscape, features detailed company profiles, and discusses the impact of COVID-19 on the market.

Report Includes:

- 28 data tables and 23 additional tables
- An up-to-date overview and analysis of the global markets for bioengineered protein drugs
- Analyses of the global market trends, with historic market revenue data (sales figures) from 2019-2021, estimates for 2022, forecasts for 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Highlights of the emerging technology trends, opportunities and gaps estimating current and future demand for bioengineered protein drugs market, and major regions and countries involved in market developments
- Estimation of the actual market size and revenue forecast for global bioengineered protein drugs market in USD million terms, and corresponding market share analysis by drug type, disease type, and region
- In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott-international.com

www.scott-international.com

industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall biopharmaceutical industry

- Discussion of the regulatory aspects and standards for bioengineered protein therapeutics, newly approved products, underlying clinical trials for all phases and list of vaccines, and the COVID-19 impact on the progress of this market
- Insight into the recent industry structure, competitive aspects of each product segment, increasing investment on R&D activities to develop new and improved therapies, market development strategies, and company value share analysis
- Identification of the major companies involved in the production and modification of protein drugs, and analysis of the company competitive landscape based on their recent developments, financial performance, and segmental revenues
- Descriptive company profiles of the leading global players, including AbbVie Inc., AstraZeneca plc, GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMS) Co., Pfizer Inc., Merck and Co., and Sanofi S.A.

Executive Summary

Summary:

Bioengineered protein drugs are widely used due to their high specificity, enhanced efficacy, affinity, solubility, and low toxicity. Advances in protein synthesis have increased the complexity of bioengineered proteins being produced for therapeutic purposes. Continued development in protein drug manufacturing technologies, growing incidence of chronic diseases, the larger elderly population, improved protein-based drug efficacy, and advancements in drug delivery systems will boost the bioengineered protein drugs market. Innovations in protein drugs are accelerating quickly. For example, in the last two years (2021 and 2022), REDACTED, or REDACTED% of all novel drug and biological product approvals, were for bioengineered protein drugs. The presence of high unmet needs and the vast potential for innovation offers tremendous growth potential for the market.

The cost of developing and producing bioengineered protein drugs is dramatically higher than for conventional (small molecule) medications and involves lengthy complex manufacturing processes and stringent regulatory requirements. The market is less susceptible to generic competition than small molecule drugs. Large molecule or protein drugs do not have the same kind of generic competition as small molecule drugs and have a longer shelf-life in terms of patent protection. Over the past three decades, bioengineered protein drugs have revolutionized the treatment of infectious diseases, cancer, and chronic immunological diseases. Pharmaceutical manufacturers are focused on developing and manufacturing novel bioengineered protein drugs for cancer, autoimmune disorders, and other life-threatening disease treatments. This is evidenced by the growing competition in the bioengineered protein drugs market.

The global bioengineered protein drugs market was estimated to have been worth \$REDACTED billion in 2021. Between 2022 and 2027, the bioengineered protein drugs market is predicted to grow at a compound annual growth rate (CAGR) of REDACTED%, leading to a market value of \$REDACTED billion in 2027. An aging population with a myriad of chronic diseases, the need for more effective and targeted therapeutics, and continuous innovation in bioengineered protein drugs are driving the bioengineered protein drugs market.

Table of Contents:

Table of Contents

Chapter 1 Introduction

1.1 Study Goals and Objectives

1.2 Scope of This Report

1.3 Methodology and Information Sources

1.4 What's New in This Update?

1.5 Geographic Breakdown

1.6 Analyst's Credentials

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.7 BCC Custom Research
- 1.8 Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Market and Technology Background
 - 3.1 Protein Drugs Overview
 - 3.2 Bioengineered Protein Drugs
 - 3.3 Manufacturing Technologies
 - 3.3.1 Fractionation/Extraction from Natural Sources (Human/Animal)
 - 3.3.2 Microbial Fermentation and Bioreactors
 - 3.3.3 Transgenics
 - 3.3.4 Mammalian Cell Culture
- Chapter 4 Market Dynamics
 - 4.1 Market Drivers
 - 4.1.1 Growing and Aging Population
 - 4.1.2 Increasing Prevalence of Chronic Diseases
 - 4.1.3 Advancements in Manufacturing Technologies
 - 4.1.4 New Product Launches and Label Expansions
 - 4.1.5 Premium Pricing
 - 4.1.6 Collaborations and Licensing Agreements
 - 4.2 Market Challenges
 - 4.2.1 Evolving Regulatory Scenario
 - 4.2.2 Accelerating Biosimilars Market
- Chapter 5 Market Breakdown by Drug Type
 - 5.1 Overview
 - 5.2 Monoclonal Antibodies (mAbs)
 - 5.2.1 Types of mAbs
 - 5.3 Peptide Hormones
 - 5.3.1 Types of Peptide Hormones
 - 5.4 Vaccines
 - 5.4.1 Types of Vaccines
 - 5.5 Fusion Proteins
 - 5.5.1 Types of Fusion Proteins
 - 5.6 Blood Factors
 - 5.6.1 Types of Blood Factors
 - 5.7 Peptide Antibiotics
 - 5.7.1 Types of Peptide Antibiotics
 - 5.8 Cytokines
 - 5.8.1 Types of Cytokines
 - 5.9 Therapeutic Enzymes
 - 5.9.1 Types of Therapeutic Enzymes
 - 5.10 Global Market for Bioengineered Protein Drugs, by Type
 - 5.10.1 Monoclonal Antibodies (mAbs)
 - 5.10.2 Peptide Hormones
 - 5.10.3 Vaccines
 - 5.10.4 Blood Factors and Peptide Antibiotics
 - 5.10.5 Fusion Proteins
 - 5.10.6 Cytokines

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.10.7 Therapeutic Enzymes
- Chapter 6 Market Breakdown by Disease
 - 6.1 Overview
 - 6.2 Autoimmune Diseases and Other Immunodeficiency Disorders
 - 6.3 Solid Tumors
 - 6.4 Diabetes
 - 6.4.1 Type 1 Diabetes
 - 6.4.2 Type 2 Diabetes
 - 6.4.3 Gestational Diabetes
 - 6.5 Infectious Diseases
 - 6.5.1 Pneumococcal
 - 6.5.2 Diphtheria, Tetanus
 - 6.5.3 Human Papillomavirus (HPV)
 - 6.5.4 MMR
 - 6.5.5 Influenza
 - 6.5.6 Hepatitis A
 - 6.5.7 Others
 - 6.6 Blood Disorders
 - 6.6.1 Bleeding Disorders
 - 6.6.2 Anemia
 - 6.6.3 Blood Cancer
 - 6.6.4 Paroxysmal Nocturnal Hemoglobinuria
 - 6.7 Growth Hormone Disorders, Enzyme Deficiency Disorders, and Infertility
 - 6.8 Others
 - 6.8.1 Osteoporosis
 - 6.8.2 Asthma
 - 6.8.3 Eye Disorders and Diseases
 - 6.8.4 Transplants
 - 6.8.5 Cardiovascular Diseases
 - 6.8.6 Respiratory Syncytial Virus Infection
 - 6.8.7 Skin Diseases
 - 6.9 Global Market for Bioengineered Protein Drugs, by Disease
 - 6.9.1 Autoimmune Diseases and Other Immunodeficiency Disorders
 - 6.9.2 Solid Tumors
 - 6.9.3 Diabetes
 - 6.9.4 Infectious Diseases
 - 6.9.5 Blood Disorders
 - 6.9.6 Growth Hormone Disorders, Enzyme Disorders, and Infertility
 - 6.9.7 Others
- Chapter 7 Market Breakdown by Region
 - 7.1 Global Markets for Bioengineered Protein Drugs, by Region
 - 7.1.1 North America Market Revenue, by Drug Type
 - 7.1.2 Europe Market Revenue, by Drug Type
 - 7.1.3 Emerging Markets Revenue, by Drug Type
- Chapter 8 Regulatory Aspects and New Approvals
 - 8.1 New Approvals
 - 8.1.1 Monoclonal Antibodies (mAbs)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1.2 Peptide Hormones
- 8.1.3 Vaccines
- 8.1.4 Blood factors
- 8.1.5 Peptide Antibiotics
- 8.1.6 Therapeutic Enzymes
- 8.1.7 Cytokines
- 8.1.8 Fusion Protein
- Chapter 9 Competitive Landscape
 - 9.1 Overview
 - 9.2 Blockbuster Bioengineered Protein Pharmaceutical Brands
 - 9.3 Monoclonal Antibodies
 - 9.3.1 Market Share
 - 9.3.2 Ten Top-Selling Monoclonal Antibodies
 - 9.4 Peptide Hormones
 - 9.4.1 Market Share
 - 9.5 Vaccines (Excluding COVID-19)
 - 9.5.1 Market Share
 - 9.6 Blood Factors and Peptide Antibiotics
 - 9.6.1 Key Players in Recombinant Blood Factors Market
 - 9.6.2 Key players in Peptide Antibiotics Market
 - 9.7 Fusion Proteins
 - 9.7.1 Market Share
 - 9.8 Cytokines
 - 9.8.1 Market Share
 - 9.9 Therapeutic Enzymes
 - 9.9.1 Market Share
- Chapter 10 Emerging Trends/Upcoming Technologies in the Market
 - 10.1 Bi- and Multi-Specific Antibodies
 - 10.1.1 Oral GLP-1 Therapy
 - 10.1.2 Accelerating Rare Disease Research Worldwide
 - 10.2 Key Trends in Biopharmaceutical Industry
- Chapter 11 Impact of COVID-19 Pandemic
 - 11.1 Overview
 - 11.2 Impact on Bioengineered Protein Drugs Market
 - 11.2.1 Impact on the mAbs Market
 - 11.2.2 Impact on Peptide Hormone Market
 - 11.2.3 Impact on Vaccines Market
 - 11.2.4 Impact on Blood Factors and Peptide Antibiotics Market
 - 11.2.5 Impact on Fusion Protein Market
 - 11.2.6 Impact on Cytokines Market
 - 11.2.7 Impact on Therapeutic Enzyme Market
- Chapter 12 Company Profiles
 - ABBVIE INC.
 - ADMA BIOLOGICS INC.
 - AMGEN INC.
 - ASTRAZENECA PLC
 - BAYER PHARMACEUTICALS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

BIONTECH SE
BRISTOL-MYERS SQUIBB
CSL LTD.
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GRIFOLS S.A.
JOHNSON & JOHNSON
MERCK & CO., INC.
NOVARTIS AG
NOVO NORDISK A/S
OCTAPHARMA AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO., LTD.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Markets for Bioengineered Protein Drugs

Market Research Report | 2023-03-16 | 185 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-02"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

